← Peptide library
Peptide comparison
This page compares tirzepatide and semaglutide side by side, drawing on reconstitution and dosing-reference data for both. It lays out each compound’s regulatory status, evidence tier, route of administration, dosing frequency, and the dose range cited in current labeling. The information is presented for reference only and is not medical advice or a recommendation to use either product.
Tirzepatide
Semaglutide
FDA-approved prescription for labeled indications
FDA-approved prescription for labeled indications
Current regulator label
Current regulator label
Subcutaneous
Subcutaneous
Once weekly
Once weekly
2.5–15 mg
0.25–2.4 mg
Tirzepatide vs Semaglutide: at a glance
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Regulatory status | FDA-approved prescription for labeled indications | FDA-approved prescription for labeled indications |
| Route | Subcutaneous | Subcutaneous |
| Dosing frequency | Once weekly | Once weekly |
| Published range | 2.5-15 mg | 0.25-2.4 mg |
| Evidence basis | Current regulator label | Current regulator label |
| What the source describes | Start 2.5 mg weekly; labeled maintenance 5, 10, or 15 mg weekly; max 15 mg | Wegovy: 0.25 mg weekly weeks 1-4, then 0.5, 1.0, 1.7; usual maintenance 2.4 mg |
| Formulation | Commercial Zepbound is supplied pre-mixed in fixed-dose pens/vials. Use actual product concentration; do not invent a reconstitution. | Commercial Wegovy is prefilled. Use only the labeled concentration or pharmacy directions. |
Every value is quoted from each compound's own labeling or published trial, listed in the sources below. A published range describes what has been studied or labeled - it is not a recommendation, and this page does not advise choosing one compound over the other. There is no valid dose conversion between two different compounds.
What is not established
| Compound | Established dose range | Stated limitation |
|---|---|---|
| Tirzepatide | 2.5-15 mg | Prescription-only; indication, titration, contraindications, interactions and monitoring are outside this calculator. |
| Semaglutide | 0.25-2.4 mg | Prescription-only; oral semaglutide uses different dosing and must not be converted with this injectable calculator. |
Sources
| Compound | Primary source | Checked |
|---|---|---|
| Tirzepatide | FDA prescribing information (Tirzepatide) - accessdata.fda.gov | 2026-06-24 |
| Semaglutide | FDA prescribing information (Semaglutide) - accessdata.fda.gov | 2026-06-24 |
INTERACTIVE
Model the dosing curve for each
Switch between tirzepatide and semaglutide to see how each one builds toward steady state across a full titration — the numbers above, drawn out week by week. Edit any step to match your own plan. Estimate and arithmetic only — not medical advice.
FDA-label titration (Mounjaro / Zepbound). Half-life ≈ 5 days.
One-compartment, first-order weekly-dosing model: k = ln(2) ÷ half-life; each dose decays as e^(−k·t) and all doses are summed (superposition). Shows an estimated relative level, not an absolute plasma concentration (no volume-of-distribution or bioavailability modeling). Titration presets reflect common labeled/trial escalations; retatrutide is investigational. Estimate and arithmetic only — not medical advice. Verify against the product label and with a clinician.
Key differences
Both tirzepatide and semaglutide are FDA-approved prescription products for their labeled indications, and the figures shown here are drawn from the current regulator label evidence tier for each. Both are administered subcutaneously and dosed once weekly. They differ in dose range: the tirzepatide reference range is 2.5-15 mg, with starting at 2.5 mg weekly and labeled maintenance options of 5, 10, or 15 mg weekly (maximum 15 mg), while the semaglutide reference range is 0.25-2.4 mg. For semaglutide, the Wegovy label describes 0.25 mg weekly during weeks 1-4, then 0.5, 1.0, and 1.7 mg, with a usual maintenance of 2.4 mg. These ranges reflect the labels themselves and are not guidance on what dose to take or which product to choose; dosing decisions belong with a licensed prescriber.
Reference comparison only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol.
Frequently asked questions
How are tirzepatide and semaglutide administered?
Both are given subcutaneously, once weekly, according to their current regulator labels. The table above shows each compound’s route and frequency side by side.
What dose ranges does this comparison reference?
It uses the labeled reference ranges shown above — tirzepatide 2.5–15 mg and semaglutide 0.25–2.4 mg. These are label ranges quoted for reference, not dosing recommendations.
Can I calculate reconstitution for both here?
Yes. Open either compound’s calculator from the buttons above to work out its concentration (mg/mL), draw volume and U-100 syringe units. The arithmetic is the same for both.
Does this page recommend one over the other?
No. It is a neutral, label-based reference. It does not assess efficacy, safety, or which product is appropriate for anyone — those decisions belong with a licensed prescriber.